Beijing Luzhu jumps over 13% as vaccine candidate moves to phase III trial

Beijing Luzhu Biotechnology

31/05/2023 05:29

** Shares of Beijing Luzhu Biotechnology Co Ltd  2480.HK  
rise as much as 13.3% to HK$30.60, highest since May 8
    ** Stock on course for third straight session of gains, if
trend holds
    ** The vaccine developer says phase II clinical trial of its
recombinant herpes zoster vaccine candidate "LZ901" in China has
been completed in May 2023 with meaningful results and the core
product is in the course of advancing to phase III clinical
trial 
    ** The Hang Seng Commerce & Industry Index  .HSNC  falls
2.5%, healthcare index  .HSCIH  drops nearly 3% and Hang Seng
Index  .HSI  declines 2.3%
    

 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))